Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SKYEY - SkyePharma PLC -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (20)	4/20/1999 4:24:00 PM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 56

SKYEY's Paxil CR sales are just beginning but there are indications that it may stake out a considerable market share in a gigantic market. The following is from a news release yesterday that discusses the decline in Lilly's Prozac sales. Paxil CR could become a real cash cow for SKYEY. John de C biz.yahoo.com > NEW YORK, April 19 (Reuters) - Prozac, a member of the popular class of anti-depressants known as Selective Serotonin Reuptake Inhibitors (SSRIs), is facing keen competition from other SSRIs such as SmithKline Beecham's (quote from Yahoo! UK & Ireland: SB.L) Paxil and Celexa launched last summer by Forest Laboratories Inc (FRX - news). Gordon who estimated that Prozac had global sales of $2.8 billion in 1998, said he had expected annual sales of the blockbuster drug to continue growing about 5 percent a year at least through the year 2000.